Patrick J. Worth

Dr. Patrick J. Worth

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
AFAmy S. Farrell
Amy S. Farrell
MJMeghan Morrison Joly
Meghan Morrison Joly
BABrittany Allen-Petersen
Brittany Allen-Petersen
PWPatrick J. Worth
Patrick J. Worth
CLChristian Lanciault
Christian Lanciault
RSRosalie C. Sears
Rosalie C. Sears
Intratumoral phenotypic heterogeneity has been described in many tumor types, where it can contribute to drug resistance and disease recurrence. We analyzed ductal and neuroendocrine markers in pancreatic ductal adenocarcinoma, revealing heterogeneous expression of the neuroendocrine marker Synaptophysin within ductal lesions. Higher percentages of Cytokeratin-Synaptophysin dual positive tumor cells correlate with shortened disease-free survival. We observe similar lineage marker heterogeneity in mouse models of pancreatic ductal adenocarcinoma, where lineage tracing indicates that Cytokeratin-Synaptophysin dual positive cells arise from the exocrine compartment. Mechanistically, MYC binding is enriched at neuroendocrine genes in mouse tumor cells and loss of MYC reduces ductal-neuroendocrine lineage heterogeneity, while deregulated MYC expression in KRAS mutant mice increases this phenotype. Neuroendocrine marker expression is associated with chemoresistance and reducing MYC levels decreases gemcitabine-induced neuroendocrine marker expression and increases chemosensitivity. Altogether, we demonstrate that MYC facilitates ductal-neuroendocrine lineage plasticity in pancreatic ductal adenocarcinoma, contributing to poor survival and chemoresistance.

1 June 2009 in The American Journal of Pathology
Verified
Journal Article
Closed access
ATAlan A. Thomay
Alan A. Thomay
JDJean M. Daley
Jean M. Daley
ESEdmond Sabo
Edmond Sabo
PWPatrick J. Worth
Patrick J. Worth
LSLeslie J. Shelton
Leslie J. Shelton
JAJorge E. Albina
Jorge E. Albina

4 March 2020 in Pancreas
Verified
Journal Article
Closed access
MSMalcolm H. Squires
Malcolm H. Squires
PWPatrick J. Worth
Patrick J. Worth
BKBhavana Konda
Bhavana Konda
MSManisha H. Shah
Manisha H. Shah
MDMary E. Dillhoff
Mary E. Dillhoff
JCJordan Cloyd
Jordan Cloyd
Objectives: The combination chemotherapy regimen capecitabine/temozolomide (CAPTEM) is efficacious for metastatic well-differentiated pancreatic neuroendocrine tumors (PNETs), but its role in the neoadjuvant setting has not been established. Methods: The outcomes of all patients with locally advanced or resectable metastatic PNETs who were treated with neoadjuvant CAPTEM between 2009 and 2017 at 2 high-volume institutions were retrospectively reviewed. Results: Thirty patients with locally advanced PNET (n = 10) or pancreatic neuroendocrine hepatic metastases (n = 20) received neoadjuvant CAPTEM. Thirteen patients (43%) exhibited partial radiographic response (PR), 16 (54%) had stable disease, and 1 (3%) developed progressive disease. Twenty-six (87%) patients underwent resection (pancreatectomy [n = 12], combined pancreatectomy and liver resection [n = 8], or major hepatectomy alone [n = 6]); 3 (18%) declined surgery despite radiographic PR, and 1 (3%) underwent aborted pancreatoduodenectomy. Median primary tumor size was 5.5 cm, and median Ki-67 index was 3.5%. Rates of PR were similar across tumor grades (P = 0.24). At median follow-up of 49 months, median progression-free survival was 28.2 months and 5-year overall survival was 63%. Conclusions: Neoadjuvant CAPTEM is associated with favorable radiographic objective response rates for locally advanced or metastatic PNET and may facilitate selection of patients appropriate for surgical resection.

15 August 2015 in Surgical Endoscopy
Verified
Journal Article
Closed access
PDF file
PWPatrick J. Worth
Patrick J. Worth
TKTaranjeet Kaur
Taranjeet Kaur
BDBrian S. Diggs
Brian S. Diggs
BSBrett C. Sheppard
Brett C. Sheppard
JHJohn G. Hunter
John G. Hunter
JDJames P. Dolan
James P. Dolan

1 October 2015 in The American Journal of Surgery
Verified
Journal Article
Closed access
PWPatrick J. Worth
Patrick J. Worth
NKNicholas R. Kunio
Nicholas R. Kunio
ISIssac Siegfried
Issac Siegfried
BSBrett C. Sheppard
Brett C. Sheppard
EGErin W. Gilbert
Erin W. Gilbert

27 March 2020 in Surgical Endoscopy
Verified
Journal Article
Closed access
PDF file
LMLaura Mazer
Laura Mazer
PWPatrick J. Worth
Patrick J. Worth
BVBrendan Visser
Brendan Visser